Multiple Myeloma Coverage from Every Angle

Saad Z. Usmani, MD, on The Challenges of Administering a New Triple Regimen in Myeloma

Posted: Wednesday, December 11, 2019

Saad Z. Usmani, MD, of the Levine Cancer Institute, discusses the logistics of ensuring adherence to the complex three-drug regimen of carfilzomib, dexamethasone, and daratumumab when the injectable agents are on different schedules and may cause different adverse events.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.